CY1114030T1 - Ομοιογενη παρασκευασματα toy il-29 - Google Patents

Ομοιογενη παρασκευασματα toy il-29

Info

Publication number
CY1114030T1
CY1114030T1 CY20131100436T CY131100436T CY1114030T1 CY 1114030 T1 CY1114030 T1 CY 1114030T1 CY 20131100436 T CY20131100436 T CY 20131100436T CY 131100436 T CY131100436 T CY 131100436T CY 1114030 T1 CY1114030 T1 CY 1114030T1
Authority
CY
Cyprus
Prior art keywords
amino acid
seq
cysteine
toy
acid residues
Prior art date
Application number
CY20131100436T
Other languages
Greek (el)
English (en)
Inventor
Lowell J Brady
Kevin M Klucher
Chung Chan
Dennis L Dong
Hong Y Liu
Paul O Sheppard
Thomas R Bukowski
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of CY1114030T1 publication Critical patent/CY1114030T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20131100436T 2003-08-07 2013-05-31 Ομοιογενη παρασκευασματα toy il-29 CY1114030T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49319403P 2003-08-07 2003-08-07
US55184104P 2004-03-10 2004-03-10
US55914204P 2004-04-02 2004-04-02
EP10173335A EP2251353B1 (en) 2003-08-07 2004-08-09 Homogeneous preparations of IL-29

Publications (1)

Publication Number Publication Date
CY1114030T1 true CY1114030T1 (el) 2016-07-27

Family

ID=34279787

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100436T CY1114030T1 (el) 2003-08-07 2013-05-31 Ομοιογενη παρασκευασματα toy il-29

Country Status (15)

Country Link
US (38) US7157559B2 (enExample)
EP (4) EP2251353B1 (enExample)
JP (2) JP4808157B2 (enExample)
CN (1) CN1910200A (enExample)
AT (1) ATE388963T1 (enExample)
AU (1) AU2004270652B2 (enExample)
CA (1) CA2534907C (enExample)
CY (1) CY1114030T1 (enExample)
DE (1) DE602004012424T2 (enExample)
DK (2) DK1668031T3 (enExample)
ES (2) ES2405209T3 (enExample)
IL (1) IL210381A0 (enExample)
PL (1) PL2251353T3 (enExample)
PT (1) PT2251353E (enExample)
WO (1) WO2005023862A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP4377126B2 (ja) * 2000-06-30 2009-12-02 ザイモジェネティクス,インコーポレイティド インターフェロン−様タンパク質zcyto21
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
JP2006509041A (ja) * 2002-10-23 2006-03-16 ザイモジェネティクス,インコーポレイティド Il−28およびil−29を用いるウイルス感染を治療するための方法
ES2351976T3 (es) 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
DK1668031T3 (da) * 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
EP1750749A2 (en) * 2004-04-02 2007-02-14 ZymoGenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
EP1793845A2 (en) * 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
US20060228329A1 (en) * 2005-01-28 2006-10-12 Brady Lowell J Homogeneous preparations of IL-31
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
JP4987001B2 (ja) * 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのil28およびil29の短縮型システイン変異体の使用法
SI1931704T1 (sl) * 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN101918440B (zh) * 2007-09-20 2015-04-22 联邦科学技术研究组织 禽类细胞因子及编码其的遗传序列的应用
US8354125B2 (en) 2007-10-27 2013-01-15 Grant Gallagher Ex-vivo treatment of peripheral blood leukocytes with IFN-λ
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
CN105535961A (zh) * 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
US20110165121A1 (en) * 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
CN102203125A (zh) * 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
US8363580B2 (en) * 2009-03-31 2013-01-29 Rosemount Inc. Disparate radios in a wireless mesh network
EP2362332A1 (en) 2010-02-26 2011-08-31 Seremfor, S.L.U. Method and system of auto checking personal protective equipment, systems and technical work instructions as regards labour risk prevention
CA2805086C (en) * 2010-05-13 2020-10-20 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
WO2012065755A1 (en) * 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
CN102559737A (zh) * 2011-12-13 2012-07-11 江南大学 一种人白细胞介素29的变异体及其制备方法
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EP2922870B1 (en) * 2012-11-21 2019-08-07 The Governors of the University of Alberta Immunomodulatory peptides and methods of use thereof
US9464321B2 (en) * 2013-03-15 2016-10-11 Medical Diagnostic Laboratories, Llc Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans
WO2015103749A1 (en) * 2014-01-08 2015-07-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104672318A (zh) * 2014-12-17 2015-06-03 江南大学 一种肽链第43位赖氨酸定点突变为亮氨酸的人白介素-29变异体
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN105037523B (zh) * 2015-06-25 2019-02-19 北京三元基因药业股份有限公司 干扰素突变体及其聚乙二醇衍生物
ES2844629T3 (es) 2015-11-04 2021-07-22 Eiger Biopharmaceuticals Inc Tratamiento de la infección por el virus de la hepatitis delta
KR102508651B1 (ko) 2015-12-23 2023-03-13 더 존스 홉킨스 유니버시티 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
ES3008560T3 (en) 2016-02-19 2025-03-24 Eit Pharma Inc Treatment of hepatitis delta virus infection with interferon lambda
CN106047806B (zh) * 2016-08-19 2019-07-16 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的外周血细胞培养基
CA3038533A1 (en) 2016-09-30 2018-04-05 The Board Of Trustees Of The Leland Stanford Junior University Variant type iii interferons and synthekines
ES3015227T3 (en) * 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107630086B (zh) * 2017-11-13 2020-11-03 吉林大学 一种与hbv感染相关的snp分子标记及其应用
CN108070647B (zh) * 2017-12-25 2021-06-01 吉林大学 与hbv感染相关的基因单体型及其应用
CN108570459B (zh) * 2018-04-10 2022-10-04 南京农业大学 一种高效发酵生产重组细菌漆酶的方法
US20230285510A1 (en) * 2020-02-06 2023-09-14 Eiger Biopharmaceuticals, Inc. Treatment of coronavirus infection with interferon lambda
US20210285000A1 (en) 2020-03-05 2021-09-16 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2021263271A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
CN115385998B (zh) * 2021-04-13 2025-08-05 杭州先为达生物科技股份有限公司 稳定的iii型干扰素蛋白及其融合蛋白
CN116219078B (zh) * 2023-05-08 2023-07-11 上海惠盾因泰生物科技有限公司 一种il-29生物学活性测定方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485332A (en) * 1892-11-01 Wagon-brake
DK170236B1 (da) 1980-01-08 1995-07-10 Biogen Inc Rekombinante DNA-molekyler, fremgangsmåde til fremstilling af et polypeptid af IFN-alfa typen og fremgangsmåde til udvælgelse af DNA-sekvenser, der koder for polypeptider af IFN-alfa typen
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en) 1984-12-06 1990-06-27 Fina Research S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU5103293A (en) 1992-09-14 1994-04-12 Oklahoma State University Immortalized cells and uses therefor
CZ221496A3 (en) 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
CA2237039A1 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US6001597A (en) 1995-11-09 1999-12-14 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
AU3891600A (en) 1999-03-18 2000-10-04 Zymogenetics Inc. Murine interferon-alpha named also zcyto13
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6376585B1 (en) 2000-06-26 2002-04-23 Apex Advanced Technologies, Llc Binder system and method for particulate material with debind rate control additive
AU2001271589A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
JP4377126B2 (ja) 2000-06-30 2009-12-02 ザイモジェネティクス,インコーポレイティド インターフェロン−様タンパク質zcyto21
CN1452633A (zh) 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
ES2334888T3 (es) 2000-11-28 2010-03-17 Zymogenetics, L.L.C. Receptor de citocina zcytor19.
JP2002308030A (ja) * 2001-04-16 2002-10-23 Yazaki Corp 車両用周辺監視装置
DE60228136D1 (de) * 2001-04-20 2008-09-18 Zymogenetics Inc Cytokin-proteinfamilie
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
PL373008A1 (en) 2001-05-10 2005-08-08 Immunex Corporation Cytokine polypeptides
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
EP1497415B1 (en) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
JP2006509041A (ja) 2002-10-23 2006-03-16 ザイモジェネティクス,インコーポレイティド Il−28およびil−29を用いるウイルス感染を治療するための方法
US7259969B2 (en) * 2003-02-26 2007-08-21 Wavezero, Inc. Methods and devices for connecting and grounding an EMI shield to a printed circuit board
DK1668031T3 (da) 2003-08-07 2008-06-30 Zymogenetics Inc Homogene præparater af IL-29
US7208541B2 (en) * 2003-08-22 2007-04-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesive
EP1750749A2 (en) * 2004-04-02 2007-02-14 ZymoGenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP4468734B2 (ja) * 2004-04-27 2010-05-26 オリンパス株式会社 映像信号処理装置と映像信号処理プログラム
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il-29工程菌
JP4987001B2 (ja) 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのil28およびil29の短縮型システイン変異体の使用法
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
DE102005000107B4 (de) * 2005-08-25 2014-03-13 Hilti Aktiengesellschaft Pneumatisch betriebenes Setzgerät
SI1931704T1 (sl) 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
US20110165121A1 (en) 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c

Also Published As

Publication number Publication date
US20070048277A1 (en) 2007-03-01
EP2251352A1 (en) 2010-11-17
US7485702B2 (en) 2009-02-03
US7468423B2 (en) 2008-12-23
CN1910200A (zh) 2007-02-07
PT2251353E (pt) 2013-05-07
US20130089517A1 (en) 2013-04-11
US7595174B2 (en) 2009-09-29
US20070055052A1 (en) 2007-03-08
US20070166282A1 (en) 2007-07-19
JP4808157B2 (ja) 2011-11-02
US20070041975A1 (en) 2007-02-22
US7495078B2 (en) 2009-02-24
PL2251353T3 (pl) 2013-08-30
US20070053875A1 (en) 2007-03-08
ES2303132T3 (es) 2008-08-01
US7157559B2 (en) 2007-01-02
US7495077B2 (en) 2009-02-24
US20070065406A1 (en) 2007-03-22
US20070172923A1 (en) 2007-07-26
US7479542B2 (en) 2009-01-20
US7514536B2 (en) 2009-04-07
US20070042470A1 (en) 2007-02-22
US7517961B2 (en) 2009-04-14
US8734776B2 (en) 2014-05-27
US20070054377A1 (en) 2007-03-08
DE602004012424D1 (de) 2008-04-24
US20070042471A1 (en) 2007-02-22
US20070054374A1 (en) 2007-03-08
IL210381A0 (en) 2011-03-31
EP1668031A2 (en) 2006-06-14
US20070048275A1 (en) 2007-03-01
US20070049737A1 (en) 2007-03-01
US8343476B2 (en) 2013-01-01
US20100104531A1 (en) 2010-04-29
US20070041936A1 (en) 2007-02-22
US20070042469A1 (en) 2007-02-22
DK1668031T3 (da) 2008-06-30
EP2251353A1 (en) 2010-11-17
US7588918B2 (en) 2009-09-15
JP2007528719A (ja) 2007-10-18
AU2004270652A1 (en) 2005-03-17
EP1927600A1 (en) 2008-06-04
US20070117967A1 (en) 2007-05-24
US20070066810A1 (en) 2007-03-22
US20070048274A1 (en) 2007-03-01
US7608427B2 (en) 2009-10-27
US7629148B2 (en) 2009-12-08
EP2251353B1 (en) 2013-03-06
US20070154446A1 (en) 2007-07-05
US7582450B2 (en) 2009-09-01
US9499598B2 (en) 2016-11-22
US20070054375A1 (en) 2007-03-08
US20070055053A1 (en) 2007-03-08
WO2005023862A3 (en) 2005-06-16
US20120004161A1 (en) 2012-01-05
US20140178333A1 (en) 2014-06-26
DE602004012424T2 (de) 2009-04-30
WO2005023862A9 (en) 2006-06-08
US20070043210A1 (en) 2007-02-22
ATE388963T1 (de) 2008-03-15
US7544779B2 (en) 2009-06-09
US20070059313A1 (en) 2007-03-15
US7629149B2 (en) 2009-12-08
US7608428B2 (en) 2009-10-27
US7662590B2 (en) 2010-02-16
US20080279816A1 (en) 2008-11-13
US20070055054A1 (en) 2007-03-08
US7662589B2 (en) 2010-02-16
HK1150618A1 (en) 2012-01-06
US20070073044A1 (en) 2007-03-29
US20070054376A1 (en) 2007-03-08
CA2534907C (en) 2014-04-29
AU2004270652B2 (en) 2010-06-03
CA2534907A1 (en) 2005-03-17
JP2011200252A (ja) 2011-10-13
US20170209542A1 (en) 2017-07-27
US20070048844A1 (en) 2007-03-01
US7727518B2 (en) 2010-06-01
US20070055051A1 (en) 2007-03-08
US20050037012A1 (en) 2005-02-17
US7638305B2 (en) 2009-12-29
US7495079B2 (en) 2009-02-24
ES2405209T3 (es) 2013-05-30
US7485701B2 (en) 2009-02-03
US20070048276A1 (en) 2007-03-01
US7588919B2 (en) 2009-09-15
WO2005023862A2 (en) 2005-03-17
US20070048843A1 (en) 2007-03-01
EP1668031B1 (en) 2008-03-12
US20070059804A1 (en) 2007-03-15
DK2251353T3 (da) 2013-06-03

Similar Documents

Publication Publication Date Title
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
DE60135393D1 (de) Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
EA200000685A1 (ru) Комплекс ifnar2/ifn
DE60228136D1 (de) Cytokin-proteinfamilie
EP0592566A4 (en) CYSTEIN-FREE IL-6 MUTANTS.
LV11816A (lv) Implantejama zalu forma
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
NO914724L (no) Somatotropiner med forandringer i alfa-spiral-1-omraadet ogkombinasjoner med andre mutasjoner
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
ES2033212A6 (es) Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs
KR930701600A (ko) 안정적이고 생물활성적인 변형된 소마토트로핀
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE416781T1 (de) Antigene modifikation von polypeptiden
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus